Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics
Graphical abstract
New multiple target drugs based on marketed neuroleptics have been designed, prepared and profiled maintaining dopamine hD2/hD3 receptor affinities, reducing histamine hH1 receptor affinities and introducing high affinity at histamine hH3 receptors (H3R). hD1/hD5 binding was heterogeneously shifted. The addition of an H3R pharmacophore to different typical and atypical neuroleptics by amide, amine or ester linkages resulted in a new profile of potential antipsychotics with low nanomolar to subnanomolar H3R affinities.
Section snippets
Acknowledgments
We thank Prof. R. Leurs (Amsterdam), Prof. J. Shine (Sydney), Dr. P. Sokoloff (Paris), and Prof. J. Lehmann (Jena) for providing cell lines expressing the histamine H1 receptor and dopamine D2S, D3 and D1, D5 receptors, respectively. We thank C. Hertzsch for the preparation of 10 and 11.
References and notes (31)
- et al.
Pharmacol. Ther.
(2004) - Celanire, S.; Lebon F.; Stark. H. In The Third Histamine Receptor:Selective Ligands as Potential Therapeutic Agents in...
- Bioprojet: Raga, M. M.; Sallares, J.; Guerrero, M.; Guglietta, A.; Arrang, J.-M.; Schwartz, J.-C.; Lecomte, J.-M.;...
- et al.
J. Neurochem.
(2006) - et al.
Drug Discov. Today
(2005) - et al.
Bioorg. Med. Chem. Lett.
(1998) - et al.
J. Org. Chem.
(1996) - et al.
Br. J. Pharmacol.
(2000) - et al.
Arch. Pharm. Pharm. Med. Chem.
(2003) - et al.
Annu. Rev. Neurosci.
(2002)
Schizophr. Bull.
Curr. Opin. Psychiatry
J. Med. Chem.
Br. J. Pharmacol.
Drug News Perspect.
Cited by (50)
Recent developments in the management of Huntington's disease
2022, Bioorganic ChemistryThe histamine H3R and dopamine D2R/D3R antagonist ST-713 ameliorates autism-like behavioral features in BTBR T+tf/J mice by multiple actions
2021, Biomedicine and PharmacotherapyCitation Excerpt :To reduce the suffering of animals, minimum number of animals were used in this study, whereas the objectives were not compromised. Synthesis and in-vitro profiling of ST-713 was carried out according to previously described methodologies in the Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Germany [27]. The reference drugs donepezil (DOZ, 1 mg/kg, i.p.) hydrochloride, Chlorpromazine (CPZ, 1.5 mg/kg, i.p.), the brain-penetrant H1R antagonist pyrilamine (PYR, 10 mg/kg, i.p.), the brain-penetrant H2R antagonist zolantidine (ZOL, 10 mg/kg, i.p.), the muscarinic anticholinergic scopolamine (SCO, 0.3 mg/kg, i.p.), the CNS-penetrant H3R agonist (R)-α-methylhistamine (RAM, 10 mg/kg, i.p.), Bovine serum albumin (BSA), primary antibodies (mouse anti-Cyclooxygenase-2 (COX-2)), mouse anti-Nuclear factor κ-B (NF-κBp65), mouse anti-inducible nitric oxide synthase (iNOS), mouse anti-actin, and secondary antibody (anti-mouse IgG) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Can wastewater analysis be used as a tool to assess the burden of pain treatment within a population?
2020, Environmental ResearchDeepCPI: A Deep Learning-based Framework for Large-scale in silico Drug Screening
2019, Genomics, Proteomics and BioinformaticsHistamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases
2016, Behavioural Brain ResearchCitation Excerpt :However, a role for the brain histaminergic system has been suggested, and a variety of ligands have been developed so far and are targeting both dopaminergic and histaminergic systems [114,115]. SCH and associated mood disorders are central disorders considered to be neurodevelopmental/neuropsychiatric with epigenetic and genetic features [116–118]. Also, dysregulations in a variety of neurotransmitter systems mainly dopamine, serotonin, GABA, and glutamate are postulated [119].
Polypharmacology of dopamine receptor ligands
2016, Progress in NeurobiologyCitation Excerpt :In fact, selective D1 receptor antagonism alone is not accepted as effective antipsychotic principle (Sedvall and Karlsson, 1999; Tauscher et al., 2004). However, potential neuroleptics with mixed D1 receptor antagonism and histamine H3 receptor antagonism were recently developed demonstrating beneficial pro-cognitive effects (Esbenshade et al., 2008; von Coburg et al., 2009). The discovery of 1-phenyl-benzapine SCH 23390 (35) (Fig. 9) (Hyttel, 1983) as D1 receptor specific antagonist boosted the development of novel benzazepines for selective targeting D1 receptors.